Adaptive Biotechnologies to Report Second Quarter 2024 Financial Results on August 1, 2024

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT), a biotechnology firm focused on harnessing the genetics of the adaptive immune system for clinical applications, will announce its Q2 2024 financial results on August 1, 2024, post-market close.

The company will host a webcast conference call at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on the same day to discuss the results. The live audio will be accessible via the 'Investors' section on their website, with an archived replay available within 24 hours after the event.

SEATTLE, July 11, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the second quarter 2024 after market close on Thursday, August 1, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Erica Jones, Associate Director, Corporate Communications
206-279-2423
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies (ADPT) report its Q2 2024 financial results?

Adaptive Biotechnologies (ADPT) will report its Q2 2024 financial results on August 1, 2024, after market close.

At what time is Adaptive Biotechnologies' Q2 2024 earnings conference call scheduled?

The Q2 2024 earnings conference call for Adaptive Biotechnologies is scheduled for 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024.

How can I access the live audio of Adaptive Biotechnologies' Q2 2024 earnings call?

The live audio of Adaptive Biotechnologies' Q2 2024 earnings call can be accessed via the 'Investors' section of the company's website.

Will there be a replay available for Adaptive Biotechnologies' Q2 2024 earnings call?

Yes, an archived replay of Adaptive Biotechnologies' Q2 2024 earnings call will be available within 24 hours after the event.